Xeomin
Xeomin is a botulinum toxin type A brand from Merz Pharma. Its nonproprietary name is incobotulinumtoxinA. Xeomin is often discussed when readers compare formulation, storage, and unit language across major type A products.
Shared serotype does not make Xeomin clinically interchangeable with Botox, Dysport, Jeuveau, Daxxify, Letybo, or other toxin brands. Its interpretation depends on Xeomin’s own label, evidence base, formulation, and market.
Who Makes Xeomin?
Section titled “Who Makes Xeomin?”Merz Pharmaceuticals GmbH manufactures Xeomin, according to the current Xeomin prescribing information on DailyMed 🔗. Readers may encounter Merz Aesthetics or Merz Therapeutics around different commercial and clinical contexts, but both belong to the wider Merz company group behind Xeomin.
Product Identity
Section titled “Product Identity”| Field | Reference point |
|---|---|
| Brand | Xeomin |
| Nonproprietary name | IncobotulinumtoxinA |
| Toxin type | Botulinum toxin type A |
| Manufacturer | Merz Pharmaceuticals GmbH |
| U.S. distributors | Merz Pharmaceuticals, LLC and Merz North America, Inc. |
Formulation Context
Section titled “Formulation Context”Xeomin is frequently described through incobotulinumtoxinA formulation language. That can be useful for distinguishing it from other type A products, but formulation shorthand should not be stretched into unsupported claims about superiority, longer duration, lower risk, or dose equivalence.
Immunogenicity and formulation discussions need product-specific evidence. A formulation feature may be relevant to interpretation without automatically determining clinical outcome.
Jürgen Frevert, Ph.D. connects the NT201 development program with Merz’s product-science history. His company-affiliated 2009 Xeomin paper 🔗 helps document how the product was developed and described; it does not independently establish clinical superiority over another toxin product.
Label Context
Section titled “Label Context”Xeomin has therapeutic and aesthetic label contexts in the United States. The current prescribing information is the anchor for U.S. claims about approved uses, preparation, warnings, and dosing language.
Regional labels may differ. A product name, toxin type, or company statement should not replace local prescribing information.